DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Tositumomab is an investigational drug.
There have been 24 clinical trials for Tositumomab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2005.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Lymphoma, Follicular. The leading clinical trial sponsors are GlaxoSmithKline, National Cancer Institute (NCI), and Southwest Oncology Group.
Recent Clinical Trials for Tositumomab
|Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma||GlaxoSmithKline||Phase 2|
|Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma||University of Michigan Cancer Center||Phase 2|
|Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma||Cephalon||Phase 2|